Symbols / ENVB $1.96 -3.30% Enveric Biosciences, Inc.
ENVB Chart
About
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.71M |
| Enterprise Value | -972.26K | Income | -12.13M | Sales | — |
| Book/sh | 3.94 | Cash/sh | 2.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | 0.00 | Forward P/E | -1.39 | PEG | — |
| P/S | — | P/B | 0.50 | P/C | — |
| EV/EBITDA | 0.11 | EV/Sales | — | Quick Ratio | 5.09 |
| Current Ratio | 5.38 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -36.24 | EPS next Y | -1.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-28 17:00 | ROA | -134.11% |
| ROE | -3.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.89M |
| Shs Float | 1.85M | Short Float | 6.77% | Short Ratio | 0.09 |
| Short Interest | — | 52W High | 17.84 | 52W Low | 1.75 |
| Beta | 0.33 | Avg Volume | 360.71K | Volume | 19.96K |
| Target Price | — | Recom | None | Prev Close | $2.03 |
| Price | $1.96 | Change | -3.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.96
Latest analyst target
3. DCF / Fair value
$-45.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.96
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-01-30 | init | HC Wainwright & Co. | — → Buy | $10 |
- ENVB stock dips after-hours on widening Q4 loss despite study progress on psychiatry drug - MSN Fri, 10 Apr 2026 19
- ENVB Forecast, Price Target & Analyst Ratings | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill hu, 09 Apr 2026 07
- If You Invested $1,000 in Enveric Biosciences Inc (ENVB) - Stock Titan Mon, 23 Mar 2026 04
- ENVB Stock Dips After-Hours On Widening Q4 Loss Despite Study Progress On Psychiatry Drug - Stocktwits Fri, 27 Mar 2026 07
- Enveric Biosciences stock soars after revealing new data on lead drug candidate - Investing.com hu, 19 Feb 2026 08
- Enveric Biosciences Announces Reverse Stock Split - Business Wire hu, 23 Oct 2025 07
- ENVB Technical Analysis & Stock Price Forecast - Intellectia AI Mon, 30 Mar 2026 21
- ‘Next Generation Mental Health’ gets Canada trademark protection for Enveric - Stock Titan Wed, 18 Mar 2026 07
- Enveric Biosciences 10-K: Pre-revenue, $8.77M operating loss, $8.77M net loss - TradingView — Track All Markets Fri, 27 Mar 2026 07
- Why Did ENVB Stock More Than Double In Value Today? - Stocktwits Wed, 10 Dec 2025 08
- A new Enveric patent broadens protection around its EB-003 drug family - Stock Titan ue, 31 Mar 2026 07
- Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Business Wire Wed, 28 Jan 2026 08
- Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits Wed, 25 Feb 2026 08
- Enveric says its depression and PTSD drug moves closer to human testing - Stock Titan Fri, 27 Mar 2026 07
- Why Is ENVB Stock Rising Today? - Stocktwits Mon, 29 Dec 2025 13
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Gross Profit |
|
—
|
—
|
—
|
—
|
| Operating Expense |
|
8.77
-8.91%
|
9.63
-47.36%
|
18.30
-8.34%
|
19.96
|
| Research And Development |
|
2.78
-2.12%
|
2.84
-60.82%
|
7.25
-9.66%
|
8.03
|
| Selling General And Administration |
|
5.79
-10.24%
|
6.45
-39.69%
|
10.70
-7.80%
|
11.61
|
| General And Administrative Expense |
|
5.79
-10.24%
|
6.45
-39.69%
|
10.70
-7.80%
|
11.61
|
| Other Gand A |
|
5.79
-10.24%
|
6.45
-27.10%
|
8.85
-23.73%
|
11.61
|
| Total Expenses |
|
8.77
-8.91%
|
9.63
-47.36%
|
18.30
-8.34%
|
19.96
|
| Operating Income |
|
-8.77
+8.91%
|
-9.63
+47.36%
|
-18.30
+8.34%
|
-19.96
|
| Total Operating Income As Reported |
|
-8.77
+8.91%
|
-9.63
+41.44%
|
-16.45
+40.00%
|
-27.42
|
| EBITDA |
|
-8.57
+7.76%
|
-9.29
+48.04%
|
-17.89
+8.34%
|
-19.52
|
| Normalized EBITDA |
|
-8.57
+7.76%
|
-9.29
+50.87%
|
-18.92
+3.11%
|
-19.53
|
| Reconciled Depreciation |
|
0.20
-40.48%
|
0.34
-17.29%
|
0.41
-6.24%
|
0.44
|
| EBIT |
|
-8.77
+8.91%
|
-9.63
+47.36%
|
-18.30
+8.30%
|
-19.95
|
| Total Unusual Items |
|
—
|
0.05
-95.54%
|
1.03
+10976.86%
|
0.01
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.05
-95.54%
|
1.03
+10976.86%
|
0.01
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-7.45
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
7.45
|
| Net Income |
|
-8.77
+8.39%
|
-9.57
+44.69%
|
-17.31
+6.45%
|
-18.50
|
| Pretax Income |
|
-8.77
+8.30%
|
-9.57
+44.59%
|
-17.26
+13.50%
|
-19.96
|
| Net Non Operating Interest Income Expense |
|
-0.00
-148.40%
|
0.00
-94.09%
|
0.00
+170.64%
|
-0.01
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.01
|
| Net Interest Income |
|
-0.00
-148.40%
|
0.00
-94.09%
|
0.00
+170.64%
|
-0.01
|
| Interest Expense |
|
—
|
—
|
—
|
0.01
|
| Interest Income Non Operating |
|
—
|
0.00
-94.09%
|
0.00
|
—
|
| Interest Income |
|
—
|
0.00
-94.09%
|
0.00
|
—
|
| Other Income Expense |
|
0.00
-96.11%
|
0.07
-93.59%
|
1.03
+10976.86%
|
0.01
|
| Other Non Operating Income Expenses |
|
0.00
-96.11%
|
0.07
|
—
|
—
|
| Gain On Sale Of Security |
|
—
|
0.05
-95.54%
|
1.03
-86.20%
|
7.46
|
| Tax Provision |
|
0.00
-100.00%
|
0.01
-69.11%
|
0.03
+101.95%
|
-1.49
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
+182.02%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
-100.00%
|
0.22
+31139.45%
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.77
+8.39%
|
-9.57
+44.63%
|
-17.29
+6.39%
|
-18.47
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.77
+8.39%
|
-9.57
+44.69%
|
-17.31
+6.45%
|
-18.50
|
| Net Income From Continuing And Discontinued Operation |
|
-8.77
+8.39%
|
-9.57
+44.69%
|
-17.31
+6.45%
|
-18.50
|
| Net Income Continuous Operations |
|
-8.77
+8.39%
|
-9.57
+44.63%
|
-17.29
+6.39%
|
-18.47
|
| Minority Interests |
|
—
|
0.00
+100.00%
|
-0.02
+42.32%
|
-0.03
|
| Normalized Income |
|
-8.77
+8.39%
|
-9.57
+47.17%
|
-18.12
+2.10%
|
-18.51
|
| Net Income Common Stockholders |
|
-12.13
-26.70%
|
-9.57
+45.16%
|
-17.46
+7.14%
|
-18.80
|
| Otherunder Preferred Stock Dividend |
|
3.36
|
0.00
|
—
|
—
|
| Diluted EPS |
|
-36.24
+84.14%
|
-228.48
+84.30%
|
-1,455.48
-646.40%
|
-195.00
|
| Basic EPS |
|
-36.24
+84.14%
|
-228.48
+84.30%
|
-1,455.48
-646.40%
|
-195.00
|
| Basic Average Shares |
|
0.33
-33.44%
|
0.50
+249.39%
|
0.14
+49.31%
|
0.10
|
| Diluted Average Shares |
|
0.33
-33.44%
|
0.50
+249.39%
|
0.14
+49.31%
|
0.10
|
| Diluted NI Availto Com Stockholders |
|
-12.13
-26.70%
|
-9.57
+45.16%
|
-17.46
+7.14%
|
-18.80
|
| Depreciation Amortization Depletion Income Statement |
|
0.20
-40.48%
|
0.34
-1.89%
|
0.34
+4.90%
|
0.33
|
| Depreciation And Amortization In Income Statement |
|
0.20
-40.48%
|
0.34
-1.89%
|
0.34
+4.90%
|
0.33
|
| Preferred Stock Dividends |
|
—
|
—
|
0.15
-50.00%
|
0.30
|
| Rent And Landing Fees |
|
—
|
0.00
-100.00%
|
1.85
|
0.00
|
| Rent Expense Supplemental |
|
—
|
0.00
-100.00%
|
1.85
|
0.00
|
| Total Other Finance Cost |
|
0.00
+148.40%
|
-0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
5.10
+65.32%
|
3.08
-28.31%
|
4.30
-78.01%
|
19.55
|
| Current Assets |
|
4.94
+80.53%
|
2.73
-23.65%
|
3.58
-80.57%
|
18.43
|
| Cash Cash Equivalents And Short Term Investments |
|
4.68
+108.72%
|
2.24
-2.05%
|
2.29
-87.09%
|
17.72
|
| Cash And Cash Equivalents |
|
4.68
+108.72%
|
2.24
-2.05%
|
2.29
-87.09%
|
17.72
|
| Cash Financial |
|
4.68
+108.72%
|
2.24
-2.05%
|
2.29
-87.09%
|
17.72
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.22
|
0.00
|
| Taxes Receivable |
|
—
|
0.00
-100.00%
|
0.22
|
0.00
|
| Prepaid Assets |
|
0.22
-56.24%
|
0.49
-1.55%
|
0.50
-29.19%
|
0.71
|
| Current Deferred Assets |
|
0.04
|
0.00
-100.00%
|
0.57
|
0.00
|
| Other Current Assets |
|
—
|
—
|
—
|
0.71
|
| Total Non Current Assets |
|
0.16
-54.24%
|
0.35
-51.56%
|
0.72
-35.92%
|
1.12
|
| Net PPE |
|
0.16
-47.92%
|
0.31
-39.73%
|
0.51
-31.56%
|
0.74
|
| Gross PPE |
|
0.83
+4.98%
|
0.80
-8.08%
|
0.87
-5.98%
|
0.92
|
| Accumulated Depreciation |
|
-0.68
-38.04%
|
-0.49
-36.81%
|
-0.36
-100.09%
|
-0.18
|
| Machinery Furniture Equipment |
|
0.03
+5.03%
|
0.03
-8.13%
|
0.03
+12.90%
|
0.03
|
| Other Properties |
|
0.81
+4.98%
|
0.77
-8.08%
|
0.84
-6.51%
|
0.89
|
| Goodwill And Other Intangible Assets |
|
0.00
-100.00%
|
0.04
-80.00%
|
0.21
-44.45%
|
0.38
|
| Goodwill |
|
—
|
—
|
—
|
0.00
|
| Other Intangible Assets |
|
—
|
—
|
—
|
0.38
|
| Total Liabilities Net Minority Interest |
|
0.92
-38.35%
|
1.49
-36.43%
|
2.34
-41.35%
|
4.00
|
| Current Liabilities |
|
0.92
-38.35%
|
1.49
-36.43%
|
2.34
-41.35%
|
4.00
|
| Payables And Accrued Expenses |
|
0.92
-38.35%
|
1.49
-35.07%
|
2.29
+5.79%
|
2.17
|
| Payables |
|
0.77
-24.51%
|
1.02
-18.16%
|
1.24
+167.90%
|
0.46
|
| Accounts Payable |
|
0.58
+11.36%
|
0.52
-57.19%
|
1.22
+163.08%
|
0.46
|
| Other Payable |
|
—
|
0.02
|
—
|
—
|
| Current Accrued Expenses |
|
0.15
-68.01%
|
0.47
-55.00%
|
1.05
-38.25%
|
1.71
|
| Total Tax Payable |
|
0.09
-67.11%
|
0.26
+1069.91%
|
0.02
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.06
|
| Current Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Other Current Liabilities |
|
—
|
0.00
-93.71%
|
0.05
-97.22%
|
1.76
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
4.18
+162.28%
|
1.59
-18.58%
|
1.96
-86.67%
|
14.67
|
| Common Stock Equity |
|
4.18
+162.28%
|
1.59
-18.58%
|
1.96
-86.67%
|
14.67
|
| Capital Stock |
|
0.01
+1778.76%
|
0.00
-69.07%
|
0.00
-91.21%
|
0.02
|
| Common Stock |
|
0.01
+1778.76%
|
0.00
-69.07%
|
0.00
-91.21%
|
0.02
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1.06
+56.57%
|
0.68
+271.26%
|
0.18
+31.81%
|
0.14
|
| Ordinary Shares Number |
|
1.06
+56.57%
|
0.68
+271.26%
|
0.18
+31.81%
|
0.14
|
| Additional Paid In Capital |
|
119.59
+10.47%
|
108.26
+7.36%
|
100.84
+6.83%
|
94.40
|
| Retained Earnings |
|
-114.85
-8.27%
|
-106.07
-9.92%
|
-96.50
-21.83%
|
-79.21
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.58
+2.44%
|
-0.59
-4.35%
|
-0.57
-6.15%
|
-0.54
|
| Minority Interest |
|
—
|
0.00
|
0.00
-100.00%
|
0.89
|
| Other Equity Adjustments |
|
-0.58
+2.44%
|
-0.59
-4.35%
|
-0.57
-6.15%
|
-0.54
|
| Total Equity Gross Minority Interest |
|
4.18
+162.28%
|
1.59
-18.58%
|
1.96
-87.42%
|
15.56
|
| Total Capitalization |
|
4.18
+162.28%
|
1.59
-18.58%
|
1.96
-86.67%
|
14.67
|
| Working Capital |
|
4.02
+222.79%
|
1.24
+0.55%
|
1.24
-91.42%
|
14.44
|
| Invested Capital |
|
4.18
+162.28%
|
1.59
-18.58%
|
1.96
-86.67%
|
14.67
|
| Total Debt |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Capital Lease Obligations |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Net Tangible Assets |
|
4.18
+169.41%
|
1.55
-11.16%
|
1.75
-87.79%
|
14.29
|
| Tangible Book Value |
|
4.18
+169.41%
|
1.55
-11.16%
|
1.75
-87.79%
|
14.29
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
—
|
| Dueto Related Parties Current |
|
0.10
-57.12%
|
0.23
|
0.00
|
—
|
| Other Equity Interest |
|
—
|
—
|
-1.82
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.14
-5.38%
|
-7.73
+45.18%
|
-14.09
+17.80%
|
-17.15
|
| Cash Flow From Continuing Operating Activities |
|
-8.14
-5.38%
|
-7.73
+45.18%
|
-14.09
+17.80%
|
-17.15
|
| Net Income From Continuing Operations |
|
-8.77
+8.39%
|
-9.57
+44.63%
|
-17.29
+6.39%
|
-18.47
|
| Depreciation Amortization Depletion |
|
0.20
-40.48%
|
0.34
-17.29%
|
0.41
-6.24%
|
0.44
|
| Depreciation |
|
0.16
-5.96%
|
0.17
-29.48%
|
0.24
-10.20%
|
0.27
|
| Amortization Cash Flow |
|
0.04
-75.00%
|
0.17
0.00%
|
0.17
+0.00%
|
0.17
|
| Depreciation And Amortization |
|
0.20
-40.48%
|
0.34
-17.29%
|
0.41
-6.24%
|
0.44
|
| Amortization Of Intangibles |
|
0.04
-75.00%
|
0.17
0.00%
|
0.17
+0.00%
|
0.17
|
| Other Non Cash Items |
|
-0.10
-123.73%
|
0.42
-77.37%
|
1.85
|
—
|
| Stock Based Compensation |
|
0.83
-47.05%
|
1.56
-27.34%
|
2.15
-17.95%
|
2.62
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
7.45
|
| Deferred Tax |
|
—
|
—
|
0.00
+100.00%
|
-1.50
|
| Deferred Income Tax |
|
—
|
—
|
0.00
+100.00%
|
-1.50
|
| Operating Gains Losses |
|
-0.00
+94.42%
|
-0.05
+95.55%
|
-1.03
+86.14%
|
-7.46
|
| Gain Loss On Investment Securities |
|
-0.00
+94.42%
|
-0.05
+95.54%
|
-1.03
+86.20%
|
-7.46
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Change In Working Capital |
|
-0.30
+30.08%
|
-0.42
-142.20%
|
-0.17
+19.71%
|
-0.22
|
| Change In Prepaid Assets |
|
0.25
+40.58%
|
0.18
+2703.12%
|
-0.01
+98.17%
|
-0.37
|
| Change In Payables And Accrued Expense |
|
-0.55
+9.12%
|
-0.60
-479.44%
|
-0.10
-139.38%
|
0.26
|
| Change In Payable |
|
-0.55
+9.12%
|
-0.60
-479.44%
|
-0.10
|
—
|
| Change In Account Payable |
|
-0.41
+50.41%
|
-0.83
-703.70%
|
-0.10
|
—
|
| Change In Other Working Capital |
|
—
|
—
|
-0.06
+40.31%
|
-0.11
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
-0.11
|
| Investing Cash Flow |
|
—
|
0.00
-100.00%
|
0.01
+102.00%
|
-0.58
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
-100.00%
|
0.01
+102.00%
|
-0.58
|
| Net PPE Purchase And Sale |
|
—
|
0.00
-100.00%
|
0.01
+102.00%
|
-0.58
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.01
+99.11%
|
-0.58
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
-0.01
+99.11%
|
-0.58
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
10.58
+37.86%
|
7.67
+671.33%
|
-1.34
-107.39%
|
18.18
|
| Cash Flow From Continuing Financing Activities |
|
10.58
+37.86%
|
7.67
+671.33%
|
-1.34
-107.39%
|
18.18
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
5.88
+74.32%
|
3.37
|
0.00
-100.00%
|
17.22
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-1.05
|
0.00
|
| Proceeds From Stock Option Exercised |
|
4.70
+4.83%
|
4.48
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
—
|
-0.18
+37.52%
|
-0.29
-130.38%
|
0.96
|
| Changes In Cash |
|
2.44
+4761.05%
|
-0.05
+99.66%
|
-15.43
-3533.70%
|
0.45
|
| Effect Of Exchange Rate Changes |
|
-0.00
-128.00%
|
0.01
+153.42%
|
-0.01
+87.68%
|
-0.08
|
| Beginning Cash Position |
|
2.24
-2.05%
|
2.29
-87.09%
|
17.72
+2.12%
|
17.36
|
| End Cash Position |
|
4.68
+108.72%
|
2.24
-2.05%
|
2.29
-87.09%
|
17.72
|
| Free Cash Flow |
|
-8.14
-5.38%
|
-7.73
+45.20%
|
-14.10
+20.48%
|
-17.73
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
-47.41%
|
0.01
|
0.00
|
| Common Stock Issuance |
|
5.88
+74.32%
|
3.37
|
0.00
-100.00%
|
17.22
|
| Issuance Of Capital Stock |
|
5.88
+74.32%
|
3.37
|
0.00
-100.00%
|
17.22
|
| Net Preferred Stock Issuance |
|
—
|
0.00
+100.00%
|
-1.05
|
0.00
|
| Preferred Stock Payments |
|
—
|
0.00
+100.00%
|
-1.05
|
0.00
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-27 View
- 8-K2026-03-27 View
- 8-K2026-02-06 View
- 8-K2026-01-28 View
- 8-K2026-01-09 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 8-K2025-12-12 View
- 8-K2025-12-11 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-10-23 View
- 8-K2025-09-18 View
- 8-K2025-09-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|